Hikma Pharmaceuticals Regulatory News (HIK)

17 Jan 2008 07:01

Hikma Pharmaceuticals Plc17 January 2008 Update on trading and reporting timetable LONDON, 17 January 2008 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX:HIK), the multinational pharmaceuticals group, confirms that since thepublication of its pre-close trading statement on 14 December 2007 there hasbeen no change to its expectations for the 2007 financial year or its outlookfor 2008. Hikma also announces that it will make the preliminary announcementof its results for the year ended 31 December 2007 on 18 March 2008, updatingthe previously advised date of 12 March 2008. Consequently, the correspondingclose period will begin on 18 January 2008. - ENDS - Enquiries: Hikma Pharmaceuticals PLCSusan Ringdal +44 20 7399 2760Investor Relations Director Brunswick GroupJon Coles / Justine McIlroy / Alex Tweed +44 20 7404 5959 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed products. Hikma operates through threebusinesses: "Branded", "Injectables" and "Generics", based principally in theMiddle East and North Africa ("MENA"), where it is a market leader and sellsacross 18 countries, the United States and Europe. In 2006, Hikma achievedrevenues of $317 million (2005 $262 million) and profit attributable toshareholders was $55 million (2005 $44 million). At 31 December 2006, the Grouphad over 2,400 employees. For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock Exchange